Brief: Neogenomics Announces Executive Leadership And Board Of Directors Succession Plan
BRIEF-Neogenomics Announces Executive Leadership And Board Of Directors Succession Plan Oct 5 (Reuters) - NeoGenomics, Inc. NEO.O:
NEOGENOMICS ANNOUNCES EXECUTIVE LEADERSHIP AND BOARD OF DIRECTORS SUCCESSION PLAN
NEOGENOMICS, - APPOINTS WARREN STONE AS CEO AND BOARD MEMBER EFFECTIVE JANUARY 4, 2027
NEOGENOMICS, - TONY ZOOK TO BECOME EXECUTIVE CHAIRMAN EFFECTIVE JANUARY 4, 2027
NEOGENOMICS, - APPOINTS MICHAEL KELLY AS LEAD INDEPENDENT DIRECTOR EFFECTIVE JANUARY 4, 2027
NEOGENOMICS, - PRELIMINARY Q3 REVENUE EXPECTED AT $209 MILLION; NGS REVENUE GROWTH ABOUT 28%
NEOGENOMICS, - FULL-YEAR TOTAL REVENUE GUIDANCE EXPECTED TO INCREASE AT MIDPOINT
NEOGENOMICS: CURRENT CHAIR LYNN TETRAULT TO CONTINUE TO SERVE AS INDEPENDENT DIRECTOR UNTIL 2027 ANNUAL MEETING AND NOT STAND FOR REELECTION THEN
Source text: ID:nBw3z67VMa
Further company coverage: NEO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NeoGenomics
See all newsU.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
NeoGenomics rises after BTIG upgrades to 'buy'
Brief: Neogenomics Announces Executive Leadership And Board Of Directors Succession Plan
Brief: Neogenomics Receives Medicare Coverage For Radar St For Immunotherapy Treatment Response Monitoring